| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039728 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(10 years from now) | |
| US10004700 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(10 years from now) | |
| US9283197 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(10 years from now) | |
Epinephrine is owned by Belcher.
Epinephrine contains Epinephrine.
Epinephrine has a total of 3 drug patents out of which 0 drug patents have expired.
Epinephrine was authorised for market use on 29 July, 2014.
Epinephrine is available in solution;intramuscular, intravenous, subcutaneous, solution;intravenous, intraocular, intramuscular, subcutaneous dosage forms.
Epinephrine can be used as emergency treatment of allergic reactions (type i), including anaphylaxis; increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; induction and maintenance of mydriasis during intraocular surgery, increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock, emergency treatment of allergic reactions (type 1), including anaphylaxis; a method of treating allergic reaction, anaphylaxis, anaphylactic shock, or combination thereof by an injection of at least one dosage of the injectable liquid pharmaceutical.
The generics of Epinephrine are possible to be released after 15 August, 2034.
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 29 July, 2014
Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating...
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic